Ben Enejo

Back to our people page Back to Locations Back to Back to Article

Partner

Ben assists top healthcare clients across Regulatory & Medical Affairs functions, as well as Commercial Strategy & Operations, with a specialty in business transformation and operational excellence initiatives.

Areas of Focus

Healthcare & Life Sciences

Education

Cranfield School of Management

Master of Business Administration

Cranfield University

M.Sc. Molecular Medicine

Nottingham Trent University

B.Sc. Physiology & Pharmacology

Past Experience

PA Consulting Group

Healthcare Management Consultant

Astra Zeneca

Patient Safety Advisor

Janssen Pharmaceuticals (Johnson & Johnson)

Pharmacovigilance Associate

Medical Gases Ltd

Sales Engineer (Business Development)

Ben is a Partner at Arthur D. Little, based in our Boston office, and a member of our global Healthcare & Life Sciences Practice.

Ben is an experienced management consultant and industry expert having worked with various global biopharmaceutical companies on strategies to accelerate the development of new medicines through to commercialization. Particular areas of expertise include clinical trial acceleration, R&D transformation including advanced technology application, increasing success for rare disease drug development and launch, patient and drug safety, and quality and compliance excellence.

Ben holds an MBA with other qualifications in Molecular Medicine, Pharmacology and Physiology, and Program management.

Management by bear, not fear!

Empathetic leadership in a world of change & disruption

Find out more

Healthcare & Life Sciences

Accelerating cures

Patient recruitment drives success in clinical trial execution — but is increasingly difficult. To overcome this challenge and achieve wins, clinical trial sponsors must inspire study teams to beat clinical trial patient-recruitment timeline targets. This Viewpoint provides insights, case studies, and data outcomes of clinical trials that achieved accelerated patient recruitment and shows how this was accomplished.

Find out more

Healthcare & Life Sciences

Why patient centricity is key to long-term pharma company success

Patient centricity seems to be an obvious focus for pharmaceutical companies. After all, their core business is to develop drugs and treatments to meet specific patient needs. Yet, patient centricity is not evident across the end-to-end pharma value chain, from identifying unmet patient needs through drug discovery and development to product availability and treatment. For example, on average, 30% of patients leave clinical trials before their scheduled treatment completion date, often because of the high burden of the trials on their lives.

Find out more

Healthcare & Life Sciences

The future of pharmacovigilance

Ben Enejo

While assessing the safety and efficacy of medicines is the bedrock in drug research, vaccine development during the COVID-19 pandemic highlighted the changes in the types of medicines developed today and the stakeholder management required for successful adoption. Enabled by new treatment paradigms, digital transformation, advanced technology applications, data availability, and the patient-centric focus, the changing ecosystem requires new capabilities in assessing the safety of medicines and managing the new entities at play.

Find out more

Healthcare & Life Sciences

Elixir of the afterlife

Emmanuel Aisabokhae, Ben Enejo

Find out more

Healthcare & Life Sciences

CAR-T on site: Forgoing the extra mile

Emmanuel Aisabokhae, Ben Enejo

CAR-T (chimeric antigen receptor T-cell) therapy involves the use of genetically re-engineered versions of a patient’s own T-cells to find cancer cells and defeat them. As of March 2020, there are two CAR-T therapies licensed for use – Kymriah® and Yescarta®. CAR-T has pushed the boundaries of medicine, and the success observed in patient treatment has created interest in the use of CAR-T to treat a number of other types of tumors. This is evidenced by the number of clinical trials involving the use of CAR-T to treat a range of cancers (Figures below).

Find out more